- Date: - -
- Venue: Online
On Tuesday the 15th September 2020 Massimo Squatrito of the Spanish National Cancer Research Centre (CNIO) in Barcelona will give a seminar entitled Overcoming chemotherapy resistance in glioblastoma. The seminar is open to members of the Department, other academic staff, students and members of Collegio A Volta. The seminar will be delivered online and the link for access is available on the poster that can be downloaded here.
Glioblastoma (GBM) is the most common and lethal primary central nervous system tumour in adults. Despite the recent advances in treatment modalities, GBM patients generally respond poorly to all therapeutic approaches and prognosis remains dismal. Radiation and chemo-resistance are characteristic of various cancer types, however it is not clear if this therapy resistance is a consequence of tumour progression or if it is intrinsically associated with the genetic events that lead to the tumour formation in the first place. Gaining insights into the pathways that determine this poor treatment response will be instrumental for the development of new therapeutic modalities. I will discuss our recent work on the genetic mechanisms that contribute to the acquired resistance to temozolomide (TMZ), the first line chemotherapeutic agent used in GBM patients.
Massimo Squatrito, born in Italy, obtained his PhD in Applied Genetics from the University of Milan, working at the European Institute of Oncology (IEO) in the laboratory of Giulio Draetta. After a short postdoctoral training in the laboratory of Bruno Amati at IEO, at the end of 2006 he joined the laboratory of Eric Holland, first as postdoctoral fellow and then as a Research Associate, at the Memorial Sloan-Kettering Cancer Center, New York (USA). Since then he has been focusing his research on the role of the DNA damage response in the process of brain tumorigenesis and response to therapy. At the end of October 2012 Massimo joined the Spanish National Cancer Research Centre (CNIO) as Junior Group Leader and director of the Seve Ballesteros Foundation Brain Tumor group.
Glioblastoma cells in culture.